Status:
RECRUITING
Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer
Lead Sponsor:
Baker Heart and Diabetes Institute
Collaborating Sponsors:
Western Health, Australia
Northern Hospital, Australia
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
40-70 years
Brief Summary
REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 years ago.
Detailed Description
REDEEM-CAD is a prospective multi-centre study in which a process of evaluating the risk of coronary artery disease is studied in cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 yea...
Eligibility Criteria
Inclusion
- A history of cancer \>5 y ago associated with potential cardiotoxicity from chemotherapy and/or radiotherapy (chiefly survivors of breast cancer, Hodgkin's lymphoma and prostate cancer).
Exclusion
- Unable to provide written informed consent to participate in this study
- Known coronary artery disease at recruitment
- History of previous coronary artery disease
- Inability to acquire interpretable CT images
- Contraindications/Intolerance to or already taking statin therapy
- Oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial
Key Trial Info
Start Date :
October 18 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
748 Patients enrolled
Trial Details
Trial ID
NCT05366153
Start Date
October 18 2023
End Date
May 1 2026
Last Update
December 4 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Tom Marwick
Hobart, Tasmania, Australia, 7000
2
Baker Heart and Diabetes Institute
Melbourne, Victoria, Australia, 3004